INVITRO INVIVO CORRELATIONS - SCIENTIFIC IMPLICATIONS AND STANDARDIZATION

被引:38
作者
CARDOT, JM
BEYSSAC, E
机构
[1] FAC PHARM CLERMONT FERRAND,DEPT BIOPHARMACEUT,POB 38,F-63001 CLERMONT FERRAND,FRANCE
[2] CIBA GEIGY LABS,BIOPHARMACEUT RES CTR,RUEIL MALMAISON,FRANCE
关键词
INVITRO INVIVO CORRELATION; A-PRIORI AND APOSTERIORI CORRELATION; REQUIREMENTS; MATHEMATICAL ASPECTS;
D O I
10.1007/BF03220014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro/in vivo correlations and the parameters that should be correlated have now been well defined in the USP and FDA working group proposals. Among the three levels of correlation defined, Level A is the most interesting one. In this paper, the Level A correlation is studied from a mathematical and a biopharmaceutical point of view. The conditions that must be met before attempting to establish correlations and the place of in vitro/in vivo correlation in modified release drug dosage form development are discussed. To establish in vitro/in vivo correlations requires a strict development methodology in order to obtain them in the most favourable conditions. In vitro/in vivo correlations should be sought as early as possible during the dosage form development (a priori correlations). If the formulation has been undertaken first and correlations sought on the finished product from subsequent in vitro tests, the predictive power of these correlations (a posteriori correlations) is thus limited and they require additional validation.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 5 条
[1]  
CIVIALE C, 1991, METHOD FIND EXP CLIN, V134, P491
[2]  
KENDALL MG, DICT STATISTICAL TER
[3]   STUDY ON THE RELEASE OF INDOMETHACIN FROM SUPPOSITORIES - INVITRO-INVIVO CORRELATION [J].
LOOTVOET, G ;
BEYSSAC, E ;
SHIU, GK ;
AIACHE, JM ;
RITSCHEL, WA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 85 (1-3) :113-120
[4]  
1988, IN VITRO IN VIVO TES
[5]  
1988, IN VITRO IN VIVO COR, P4160